Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Up 11.8% in September

Hoth Therapeutics, Inc. (NASDAQ:HOTH) was the recipient of a large increase in short interest in September. As of September 15th, there was short interest totalling 245,300 shares, an increase of 11.8% from the August 31st total of 219,400 shares. Based on an average daily volume of 3,650,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 3.6% of the shares of the stock are sold short.

Analyst Ratings Changes

Several research firms have issued reports on HOTH. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Hoth Therapeutics in a research note on Friday, August 16th. EF Hutton Acquisition Co. I upgraded shares of Hoth Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 21st.

Hoth Therapeutics Stock Performance

Hoth Therapeutics stock traded down $0.02 during trading on Tuesday, hitting $0.86. The company’s stock had a trading volume of 82,251 shares, compared to its average volume of 1,446,646. The stock’s fifty day moving average is $0.82 and its 200 day moving average is $1.03. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $1.73. The stock has a market capitalization of $4.61 million, a price-to-earnings ratio of -0.44 and a beta of 0.82.

Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.15. On average, research analysts anticipate that Hoth Therapeutics will post -1.18 EPS for the current fiscal year.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.